CONCORD, Calif.--(BUSINESS WIRE)--In the first paragraph, presentation time should read 1:00 PM ET (instead of 1:30 PM ET).
The corrected release reads:
CERUS TO PRESENT AT CANTOR FITZGERALD’S 2nd ANNUAL HEALTHCARE CONFERENCE ON JULY 13, 2016
Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus' vice president, finance and chief financial officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 1:00 PM ET on Wednesday, July 13, 2016.
A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.